Relay Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Relay Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Relay Therapeutics: 5 sponsored US clinical trials, 4 recruiting.
Relay Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PIK3CA Mutation, with 4 trials.
Upper-quartile sponsor footprint
Relay Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
NCT06789913
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
NCT05759949
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Relay Therapeutics pipeline
4 recruiting of 5 indexed (80% open); 1 completed (20%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: PIK3CA Mutation (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Relay Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.
Relay Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 80% open enrollment (± trial volume)
- Alpha Tau Medical · 80% recruiting · 5 trials
- Buck Institute for Research on Aging · 80% recruiting · 5 trials
- IDEAYA Biosciences · 80% recruiting · 10 trials
- MapLight Therapeutics · 80% recruiting · 5 trials
Related
What to do with this Relay Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Relay Therapeutics or any single study.
- 4 of Relay Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PIK3CA Mutation is the condition Relay Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PIK3CA Mutation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Relay Therapeutics pipeline card: 5 registered trials from official public datasets.Report a data error.